Clinical presentation of Attenuated Psychosis Syndrome in children and adolescents: Is there an age effect?

Psychiatry Res

Child and Adolescence Neuropsychiatry Unit, Department of Neuroscience, Children Hospital Bambino Gesù, Piazza Sant'Onofrio 4, 00165 Rome, Italy; Developmental Imaging and Psychopathology Laboratory, University of Geneva School of Medicine, Geneva, Switzerland. Electronic address:

Published: June 2017

There is limited research on clinical features related to age of presentation of the Attenuated Psychosis Syndrome in children and adolescents (CAD). Based on findings in CAD with psychosis, we hypothesized that an older age at presentation of Attenuated Psychosis Syndrome would be associated with less severe symptoms and better psychosocial functioning than presentation in childhood or younger adolescence. Ninety-four CAD (age 9-18) meeting Attenuated Psychosis Syndrome criteria participated in the study. The sample was divided and compared according to the age of presentation of Attenuated Psychosis Syndrome (9-14 vs 15-18 years). The predictive value of age of Attenuated Psychosis Syndrome presentation was investigated using receiver operating characteristic (ROC)-curve calculations. The two Attenuated Psychosis Syndrome groups were homogeneous in terms of gender distribution, IQ scores and comorbid diagnoses. Older Attenuated Psychosis Syndrome patients showed better functioning and lower depressive scores. ROC curves revealed that severity of functional impairment was best predicted using an age of presentation cut-off of 14.9 years for social functioning and 15.9 years for role functioning. This study partially confirmed our hypothesis; older age at presentation of Attenuated Psychosis Syndrome was associated with less functional impairment, but age was not associated with psychotic symptoms.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psychres.2017.02.050DOI Listing

Publication Analysis

Top Keywords

attenuated psychosis
36
psychosis syndrome
36
presentation attenuated
20
age presentation
20
psychosis
10
attenuated
9
syndrome
9
age
9
syndrome children
8
children adolescents
8

Similar Publications

Three-year course of clinical high-risk symptoms for psychosis in the community: a latent class analysis.

Epidemiol Psychiatr Sci

January 2025

University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.

Aims: Clinical high-risk for psychosis (CHR-P) states exhibit diverse clinical presentations, prompting a shift towards broader outcome assessments beyond psychosis manifestation. To elucidate more uniform clinical profiles and their trajectories, we investigated CHR-P profiles in a community sample.

Methods: Participants ( = 829; baseline age: 16-40 years) comprised individuals from a Swiss community sample who were followed up over roughly 3 years.

View Article and Find Full Text PDF

: Cannabidiol (CBD) is an approved treatment for childhood epilepsies and a candidate treatment for several other CNS disorders. However, it has poor oral bioavailability. We investigated the effect of a novel lipid formulation on its absorption in humans and on its tissue distribution in mice.

View Article and Find Full Text PDF

To date, no psychotropic medication has shown to effectively halt progression to psychosis among individuals at Clinical High-Risk for psychosis (CHR), fueling the search for novel therapeutic agents. Recent evidence supports Palmitoylethanolamide (PEA) signaling as a potential psychosis biomarker, also indicating a therapeutic role for its supplementation in the treatment of psychotic disorders. Nonetheless, the effect of sustained PEA intake in CHR subjects has never been explored so far.

View Article and Find Full Text PDF

Objective: Identification of therapeutic targets in the treatment of adolescent depression with attenuated symptoms of schizophrenia and assessment of the effectiveness of therapeutic interventions.

Material And Methods: One hundred and twenty-three patients (mean age 19.6±2.

View Article and Find Full Text PDF
Article Synopsis
  • Individuals at ultra-high risk (UHR) for psychosis with persistent attenuated psychotic symptoms (APS) show worse clinical and functional outcomes compared to those who remit, closely resembling individuals who transition to psychosis.
  • After an initial period, the symptom and functioning trajectories for those with persistent APS diverge quickly from those who remit.
  • Prediction of non-remission improves significantly with longitudinal data (6-month follow-up) rather than relying on baseline data alone, indicating the need for consistent monitoring and intervention for UHR individuals with persistent APS.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!